Deciphera Pharmaceuticals (NASDAQ:DCPH) had its price target lifted by research analysts at Guggenheim from $44.00 to $66.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 74.28% from the company’s current price.
A number of other analysts have also issued reports on the company. Piper Jaffray Companies boosted their price target on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, June 3rd. They noted that the move was a valuation call. ValuEngine upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. BidaskClub upgraded Deciphera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 2nd. Zacks Investment Research upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $26.00 price target for the company in a report on Monday, August 5th. Finally, Deutsche Bank initiated coverage on Deciphera Pharmaceuticals in a report on Thursday, July 18th. They issued a “buy” rating and a $42.00 price target for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $47.90.
Shares of NASDAQ DCPH opened at $37.87 on Tuesday. The company has a quick ratio of 7.26, a current ratio of 7.26 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $762.39 million, a price-to-earnings ratio of -13.43 and a beta of 2.34. The company has a 50 day moving average price of $22.85. Deciphera Pharmaceuticals has a 52-week low of $18.55 and a 52-week high of $42.99.
In related news, insider Daniel Lee Flynn sold 148,107 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $40.92, for a total value of $6,060,538.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Thomas Patrick Kelly sold 2,100 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $25.20, for a total transaction of $52,920.00. The disclosure for this sale can be found here. Insiders sold 185,607 shares of company stock valued at $7,536,409 in the last three months. 7.02% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its stake in Deciphera Pharmaceuticals by 4.2% in the second quarter. Bank of America Corp DE now owns 26,052 shares of the company’s stock worth $588,000 after buying an additional 1,062 shares in the last quarter. Bank of Montreal Can bought a new position in Deciphera Pharmaceuticals in the second quarter worth approximately $28,000. BNP Paribas Arbitrage SA raised its stake in Deciphera Pharmaceuticals by 61,033.3% in the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after buying an additional 1,831 shares in the last quarter. Virtus ETF Advisers LLC raised its stake in Deciphera Pharmaceuticals by 17.7% in the second quarter. Virtus ETF Advisers LLC now owns 12,449 shares of the company’s stock worth $281,000 after buying an additional 1,871 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Deciphera Pharmaceuticals by 89.2% in the second quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock worth $95,000 after buying an additional 1,913 shares in the last quarter. 59.10% of the stock is owned by institutional investors.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.